Accordingly, numerous clinical trials highlighted that TLR-7/9 agonists administration, individually or in combination with ICB therapies, has the potential to stimulate specific T cell response and subsequent tumor regression (38, 39), even for patients with MM (37). The gene discussed is TLR7; the disease is neoplasm.